BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families

BMC Medical Genetics

Edvins Miklasevics¹  Janis Gardovskis¹  Dagnija Kalniete¹  Andris Gardovskis¹  Arvids Irmejs¹  Karina Aksenoka¹  Jekaterina Zestkova¹  Miki Nakazawa-Miklasevica¹  Dace Berzina¹ 

[1]Institute of Oncology, Riga Stradins University, Dzirciema street 16, LV1007, Riga, Latvia

关键词: Mutation analysis;    Hereditary cancer families;    Breast cancer;    BRCA2;   

Others  :  1137114
DOI  :  10.1186/1471-2350-14-61

 received in 2012-07-06, accepted in 2013-06-11,  发布年份 2013

【 摘 要 】

Background

The estimated ratio of hereditary breast/ovarian cancer (HBOC) based on family history is 1.5% in Latvia. This is significantly lower than the European average of 5–10%. Molecular markers like mutations and SNPs can help distinguish HBOC patients in the sporadic breast and ovarian cancer group.

Methods

50 patients diagnosed with HBOC in the Latvian Cancer Registry from January 2005 to December 2008 were screened for BRCA1 founder mutation-negatives and subjected to targeted resequencing of BRCA1 and BRCA2 genes. The newly found mutations were screened for in the breast and ovarian cancer group of 1075 patients by Real Time-PCR/HRM analysis and RFLP.

Results

Four BRCA2 mutations including three novel BRCA2 frameshift mutations and one previously known BRCA2 frameshift mutation and one BRCA1 splicing mutation were identified. Two of the BRCA2 mutations were found in a group of consecutive breast cancer patients with a frequency of 0.51% and 0.38%.

Conclusions

Molecular screening of sequential cancer patients is an important tool to identify HBOC families.

【 授权许可】

   
2013 Berzina et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77:2318-2324.
• [2]Plakhins G, Irmejs A, Gardovskis A, et al.: Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia. BMC Med Genet 2011, 12:147. BioMed Central Full Text
• [3]Vanags A, Štrumfa I, Gardovskis A, et al.: Population screening for hereditary and familial cancer syndromes in Valka district of Latvia. Hered Cancer Clin Pract 2010, 8:8. BioMed Central Full Text
• [4]Fackenthal JD, Olopade OI: Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007, 7:937-948.
• [5]Ramus SJ, Gayther SA: The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009, 3:138-150.
• [6]Tikhomirova L, Sinicka O, Smite D, et al.: High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer 2005, 4(2):77-84.
• [7]Gardovskis A, Irmejs A, Miklaševičs E, et al.: Clinical, molecular and geographical features of hereditary breast/ovarian cancer in Latvia. Hered Cancer Clin Pract 2005, 3:71-76. BioMed Central Full Text
• [8]Wagnera T, Stoppa-Lyonnetb D, Fleischmanna E, et al.: Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 1999, 62(3):369-376.
• [9]De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K: Genotyping of frequent BRCA1/2 SNPs with unlabeled probes: a supplement to HRMCA mutation scanning, allowing the strong reduction of sequencing burden. J Mol Diagn 2009, 11:415-419.
• [10]Carvalho MA, Marsillac SM, Karchin R, et al.: Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 2007, 67:1494-1501.
• [11]Lubinski J, Phelan CM, Ghadirian P, et al.: Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 2004, 3(1):1-10.
• [12]Offit K, Levran O, Mullaney B, et al.: Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003, 95(20):1548-1551.
• [13]Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL: Characterization of common BRCA1 and BRCA2 variants. Genet Test 2002, 6:119-121.
• [14]Zhang B, Beeghly-Fadiel A, Long J, Zheng W: Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011, 12:477-488.
• [15]Johnson N, Fletcher O, Palles C, et al.: Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007, 16:1051-1057.
• [16]National Human Genome Research Institute (NHGRI): An open access on-line breast cancer mutation data base Breast Cancer Information Core (BIC). Available at: http://research.nhgri.nih.gov/bic/ webcite. [Last accessed April 24, 2012.]
• [17]Alter B, Rosenberg PS, Brody LC: Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007, 44:1-9.
• [18]Jakubowska A, Scott R, Menkiszak J, et al.: A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet 2003, 11:955-958.
• [19]Machado PM, Brandão RD, Cavaco BM, et al.: Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 2007, 25:2027-2034.
• [20]Malone KE, Daling JR, Doody DR, et al.: Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006, 66:8297-8308.